Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867015385965920256 |
|---|---|
| author | Alba López‐Bravo Ane Mínguez‐Olaondo Candela Nieves‐Castellanos Marta Ruibal‐Salgado Noemí Morollón Sánchez‐Mateos María Pilar Navarro‐Pérez Alicia Alpuente Marta Torres‐Ferrús Jésica García‐Ull Ana Gago‐Veiga David García‐Azorín Alicia González‐Martínez Álvaro Sierra Sonia Santos‐Lasaosa |
| author_facet | Alba López‐Bravo Ane Mínguez‐Olaondo Candela Nieves‐Castellanos Marta Ruibal‐Salgado Noemí Morollón Sánchez‐Mateos María Pilar Navarro‐Pérez Alicia Alpuente Marta Torres‐Ferrús Jésica García‐Ull Ana Gago‐Veiga David García‐Azorín Alicia González‐Martínez Álvaro Sierra Sonia Santos‐Lasaosa Alba López‐Bravo Ane Mínguez‐Olaondo Candela Nieves‐Castellanos Marta Ruibal‐Salgado Noemí Morollón Sánchez‐Mateos María Pilar Navarro‐Pérez Alicia Alpuente Marta Torres‐Ferrús Jésica García‐Ull Ana Gago‐Veiga David García‐Azorín Alicia González‐Martínez Álvaro Sierra Sonia Santos‐Lasaosa |
| collection | Wiley Open Access |
| contents | Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study Alba López‐Bravo Ane Mínguez‐Olaondo Candela Nieves‐Castellanos Marta Ruibal‐Salgado Noemí Morollón Sánchez‐Mateos María Pilar Navarro‐Pérez Alicia Alpuente Marta Torres‐Ferrús Jésica García‐Ull Ana Gago‐Veiga David García‐Azorín Alicia González‐Martínez Álvaro Sierra Sonia Santos‐Lasaosa Headache: The Journal of Head and Face Pain Abstract Background Calcitonin gene‐related peptide monoclonal antibodies (CGRP mAbs) are the first migraine‐specific prophylactic medication. Clinical data regarding patient treatment satisfaction (TS) with CGRP mAbs are limited. Methods A multicenter prospective cohort study was conducted in patients with ≥8 headache days/month who started treatment with erenumab, galcanezumab, or fremanezumab. Monthly migraine days (MMD), monthly headache days (MHD), Migraine Disability Assessment (MIDAS), and the six‐item Headache Impact Test (HIT‐6) scores were collected. Patients’ satisfaction with treatment (effectiveness, convenience, side effects, and global satisfaction) was assessed by the Treatment Satisfaction Questionnaire for Medication, version 1.4 (TSQM‐1.4©). Results A total of 400 patients were included. The median (interquartile range [IQR]) TS scores were high (≥70%) across all domains of the TSQM‐1.4 after 3 and 6 months of CGRP mAb therapy: 72.2 (50.0–83.3) and 83.3 (61.1–88.9) for effectiveness, 83.3 (72.2–100) and 83.3 (77.8–100) for convenience, and finally, a score of 78.6 (50.0–92.9) and 85.7 (71.4–92.9) for global satisfaction. The median (IQR) reduction in MHD and MMD was 10.0 (3.0–17.0; p < 0.001) and 8.0 (4.0–12.0; p < 0.001) days after 3 months of treatment, and 10.0 (3.0–17.0; p < 0.001) and 9.0 (5.0–17.0; p < 0.001) days after 6 months. The median (IQR) HIT‐6 score decreased from 68.0 (65.0–72.0) to 60.0 (51.0–66.0; p < 0.001) at Month 3 and to 56.0 (48.0–64.0; p < 0.001) at Month 6. Finally, the median (IQR) MIDAS score decreased from 70 (40.0–120.0) to 24 (7.8–60.0; p < 0.001) and 17 (5.0–45.0; p < 0.001) at Months 3 and 6, respectively. The median change from baseline in MMD was significantly associated with effectiveness at 3 ( β = −0.93, 95% CI −1.34 to −0.53; p < 0.001) and 6 months ( β = −1.56, 95% CI −2.15 to −0.97; p < 0.001). Similarly, reductions in MMD were significantly associated with the global satisfaction dimension of the questionnaire ( β = −0.82, 95% CI −1.27 to −0.37; p < 0.001) and ( β = −1.80, 95% CI −2.42 to −1.18; p < 0.001). Conclusions Most patients were satisfied with CGRP mAbs’ effectiveness, tolerability, and convenience in a real‐world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine. 10.1111/head.14913 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/head.14913 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_head_14913 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study Alba López‐Bravo Ane Mínguez‐Olaondo Candela Nieves‐Castellanos Marta Ruibal‐Salgado Noemí Morollón Sánchez‐Mateos María Pilar Navarro‐Pérez Alicia Alpuente Marta Torres‐Ferrús Jésica García‐Ull Ana Gago‐Veiga David García‐Azorín Alicia González‐Martínez Álvaro Sierra Sonia Santos‐Lasaosa Headache: The Journal of Head and Face Pain Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study Alba López‐Bravo Ane Mínguez‐Olaondo Candela Nieves‐Castellanos Marta Ruibal‐Salgado Noemí Morollón Sánchez‐Mateos María Pilar Navarro‐Pérez Alicia Alpuente Marta Torres‐Ferrús Jésica García‐Ull Ana Gago‐Veiga David García‐Azorín Alicia González‐Martínez Álvaro Sierra Sonia Santos‐Lasaosa Headache: The Journal of Head and Face Pain Abstract Background Calcitonin gene‐related peptide monoclonal antibodies (CGRP mAbs) are the first migraine‐specific prophylactic medication. Clinical data regarding patient treatment satisfaction (TS) with CGRP mAbs are limited. Methods A multicenter prospective cohort study was conducted in patients with ≥8 headache days/month who started treatment with erenumab, galcanezumab, or fremanezumab. Monthly migraine days (MMD), monthly headache days (MHD), Migraine Disability Assessment (MIDAS), and the six‐item Headache Impact Test (HIT‐6) scores were collected. Patients’ satisfaction with treatment (effectiveness, convenience, side effects, and global satisfaction) was assessed by the Treatment Satisfaction Questionnaire for Medication, version 1.4 (TSQM‐1.4©). Results A total of 400 patients were included. The median (interquartile range [IQR]) TS scores were high (≥70%) across all domains of the TSQM‐1.4 after 3 and 6 months of CGRP mAb therapy: 72.2 (50.0–83.3) and 83.3 (61.1–88.9) for effectiveness, 83.3 (72.2–100) and 83.3 (77.8–100) for convenience, and finally, a score of 78.6 (50.0–92.9) and 85.7 (71.4–92.9) for global satisfaction. The median (IQR) reduction in MHD and MMD was 10.0 (3.0–17.0; p < 0.001) and 8.0 (4.0–12.0; p < 0.001) days after 3 months of treatment, and 10.0 (3.0–17.0; p < 0.001) and 9.0 (5.0–17.0; p < 0.001) days after 6 months. The median (IQR) HIT‐6 score decreased from 68.0 (65.0–72.0) to 60.0 (51.0–66.0; p < 0.001) at Month 3 and to 56.0 (48.0–64.0; p < 0.001) at Month 6. Finally, the median (IQR) MIDAS score decreased from 70 (40.0–120.0) to 24 (7.8–60.0; p < 0.001) and 17 (5.0–45.0; p < 0.001) at Months 3 and 6, respectively. The median change from baseline in MMD was significantly associated with effectiveness at 3 ( β = −0.93, 95% CI −1.34 to −0.53; p < 0.001) and 6 months ( β = −1.56, 95% CI −2.15 to −0.97; p < 0.001). Similarly, reductions in MMD were significantly associated with the global satisfaction dimension of the questionnaire ( β = −0.82, 95% CI −1.27 to −0.37; p < 0.001) and ( β = −1.80, 95% CI −2.42 to −1.18; p < 0.001). Conclusions Most patients were satisfied with CGRP mAbs’ effectiveness, tolerability, and convenience in a real‐world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine. 10.1111/head.14913 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study |
| topic | Headache: The Journal of Head and Face Pain |
| url | https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14913 |